Navigation Links
New gene test for prostate cancer at hand
Date:1/17/2008

Men with susceptibility for prostate cancer will soon be identifiable through a simple DNA test. So hope scientists at the Swedish medical university Karolinska Institutet, who have shown that men carrying a combination of known risk genes run a four to five times higher risk of developing prostate cancer.

At present, men with suspected prostate cancer are identified mainly using what are known as PSA tests. However, the test has a relatively low sensitivity and better methods are needed.

In the near future, it will be possible to combine PSA tests with simple genetic tests, says Professor Henrik Grnberg at Karolinska Institutet. This means that fewer men will have to undergo unnecessary biopsies and that more prostate cancer diagnoses can be made.

It has long been known that prostate cancer is partly caused by inherited factors, which makes some men more likely to develop the disease than others. Five relatively common gene variants that affect this risk have so far been identified. However, each of these variants affects the risk only marginally, and knowledge of them has been of no real benefit to individual patients.

Now, however, a research group at Karolinska Institutet and their American colleagues have analysed for the first time the cumulative effect of these gene variants. The results, which are published in the prestigious scientific periodical The New England Journal of Medicine, shows that men who carry four or more risk variants run a four to five times greater risk of developing prostate cancer. This risk is increased even more if they also had close relatives with the disease.

According to the researchers, this is the first time that anyone has been able to demonstrate how a combination of genes affect the risk of developing the disease. Scientists the world over are currently searching for gene combinations behind common diseases like cancer, diabetes and asthma.

For the first time, this type of study has made it possible to develop a clinically viable gene test, says Professor Grnberg.


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Study finds that blood test can gauge prostate cancer risk
2. Gene markers located for hereditary prostate cancer
3. Genetic Mutations Boost Prostate Cancer Risk
4. Hormonal dietary supplements might promote prostate cancer progression
5. Common molecule notifies immune system of prostate cancer
6. Fatherhood Tied to Higher Prostate Cancer Risk
7. Fatherhood linked to prostate cancer risk
8. Combo Therapy Cuts Prostate Cancer Death Rates
9. Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
10. Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
11. Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Lakes, NJ (PRWEB) , ... December 05, 2016 ... ... recording studio teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson ... Foxx, Kelly Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... moisture measurements are consistently correct. However, regular performance testing is often neglected ... offers a solution: SmartCal™ . This innovative test substance offers a ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- M ichael Moore ... Chairman   Mission Therapeutics, a drug discovery and ... treat cancer, neurodegenerative and other diseases, announces that Dr ... January 1 st 2017. Dr Colin Goddard ... in July 2015. Michael Moore , Mission,s Founder Chairman, ...
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the ... SelG1), an anti-P-selectin antibody, reduced the median annual rate ... to placebo (1.63 vs 2.98, p=0.010) in patients with ... that the data are being featured in the official ... of Hematology (ASH) Annual Meeting and presented during the ...
Breaking Medicine Technology: